April 28th 2024
During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
MRTX849 Shows Safety, Tolerability in Treating KRAS G12C
November 29th 2019In patients whose solid<strong> </strong>tumors harbor a mutation in <em>KRAS </em>G12C, therapy with MRTX849 has produced promising responses and acceptable toxicity across 3 tumors types, according to data presented at the 2019 American Association for Cancer Research–National Cancer Institute–European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics.
Read More
Choosing Between Systemic Therapy and TACE for HCC
November 29th 2019What is the ideal first-line<strong> </strong>therapy for nonresectable, non– transplant eligible, liver-only hepatocellular carcinoma? In a debate at the 2019 Gastrointestinal Oncology Conference, Mark Yarchoan, MD, had the unenviable task of convincing the audience that systemic therapy was the way to go.
Read More
Frontline Atezolizumab Plus Bevacizumab Prolongs Survival in HCC
November 23rd 2019The frontline combination of atezolizumab and bevacizumab statistically and clinically improved progression-free survival and overall survival compared with sorafenib in patients with hepatocellular carcinoma in the phase III IMbrave150 study, according to a press release from Roche.
Read More
Treatment Options Evolve in Nonresectable, Non-Transplantable Liver-Only HCC Paradigm
November 19th 2019In an interview with Targeted Oncology, Mark Yarchoan, MD, discussed the treatment options available for patients with liver-only HCC who are not eligible for surgery or transplant. He also highlighted the different treatment options that are under investigation now for patients with HCC in the first- and second-line settings.
Read More
FDA Grants Priority Review for Nivolumab Plus Ipilimumab in Advanced HCC
November 12th 2019A supplemental Biologics License Application for the combination of nivolumab and ipilimumab for the treatment of patients with advanced hepatocellular carcinoma previously treated with sorafenib has been accepted by the FDA and given Priority Review status. The supplemental Biologics License Applicationwas given a Prescription Drug User Fee Act goal date of March 10, 2020, according to a press release from Bristol-Myers Squibb.<br />
Read More
Investigators Explore Neoadjuvant Immunotherapy in Hepatocellular Carcinoma
November 6th 2019In solid tumor oncology, an evolving treatment paradigm is getting more and more attention—and no, I’m not referring to immunotherapy. In localized solid tumors, surgery is often a standard of care, with intent being toward cure.
Read More
FDA Approves New Aprepitant Dosing Regimen for CINV After MEC
October 23rd 2019The FDA has approved a supplemental New Drug Application for a single dose of aprepitant injectable emulsion for intravenous use in patients receiving moderately emetogenic chemotherapy. The approval expands the dose for aprepitant to include a 130 mg single-dose regimen for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.<br />
Read More